SFARI is soliciting your feedback about the utility and priority of induced pluripotent (iPS) cells from individuals with high-confidence autism risk variants. Your comments will help us to create a research infrastructure that will allow the use of SFARI biospecimen resources in the most impactful way.

Six current and former SFARI Investigators are among the 213 newly elected members of the American Academy of Arts & Sciences, one of the nation’s oldest and most prestigious honorary societies.

New data were added to SFARI Gene in April 2018. This data release included updated gene scores for candidate autism risk genes, as well as the addition of new genes, animal models, and copy number variant loci associated with autism.

New Simons VIP Phase 2 data were recently added to SFARI Base. This data release included data from individuals with 16p11.2 copy number variants (CNVs), 1q21.1 CNVs and mutations in the following single genes: ADNP, ASXL3, DYRK1A, FOXP1, GRIN2B, HIVEP2, MED13L, PACS1, PPP2R5D, SCN2A, SETBP1, STXBP1 and SYNGAP1.

SFARI announces the launch of HumanBase, a Simons Foundation interactive web server for predictions and information about human genes, pathways and disorders.

SFARI announces that a new article summarizing the first year’s activities of SPARK — a SFARI-funded study that aims to recruit, engage and retain 50,000 individuals with autism spectrum disorder (ASD) and their family members — was published in the journal Neuron.

SFARI is happy to announce a new addition to the gene-scoring module of SFARI Gene: scores and rankings from an additional six published approaches to evaluating the strength of the evidence implicating each gene in autism risk.

SFARI is pleased to announce that it has awarded 13 grants in response to the Explorer Awards request for applications this year.